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Plasma  cell  leukaemia  (PCL)  is  a rare  and  aggressive  disease.  Diagnosis  is made  when  there  are  >2000/#mL
circulating  plasma  cells  in peripheral  blood  or plasmacytosis  >20%  of total  leukocyte  count.  We  report  a
case  of  a 51-year  old  man  with  generalized  bone  pain  and  constitutional  symptoms.  Blood  peripheral
smear  revealed  leukocytosis  with  39%  plasma  cells.  Bone  marrow  biopsy  showed  plasma  cell  inva-
sion,  which  conﬁrmed  the  diagnosis  of  PCL.  Additionally,  the patient  had  markers  of advanced  disease.lasma cell leukaemia
ultiple myeloma
Chemotherapy  with  vincristine,  adriamycin  and  dexamethasone  was  started.  Despite  an  initial  favourable
response,  the  patient  died  2  months  later  due  to an  infectious  complication.  PCL  has  no  established
treatment  and  has  a  dismal  prognosis,  requiring  the  achievement  of  better  data  to  improve  the disease
course.
© 2016  PBJ-Associac¸a˜o  Porto  Biomedical/Porto  Biomedical  Society.  Published  by  Elsevier  Espan˜a,
S.L.U.  This  is an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/ntroduction
Plasma cell leukaemia (PCL) is a rare lymphoproliferative disor-
er characterized by malignant proliferation of plasma cells in bone
arrow and concomitant peripheral blood involvement.1 It has
n estimated incidence of approximately 4 cases/10 000 000 per-
ons/year, accounting for 1.3–3.4% of all plasma cell discrasias.1 To
tandardize criteria for this diagnosis, Kyle et al.2 proposed an abso-
ute plasma cell count >2000/#mL or plasma cells comprising >20%
f the total white cell count in peripheral blood. PCL is classiﬁed as
rimary when it occurs in the absence of a prior history of multi-
le myeloma (MM)  or secondary when it is related to refractory or
elapsing disease.3 Clinical presentation is characterized by non-
peciﬁc symptoms1 and median age at diagnosis is usually above
0 years.3 PCL is an extremely aggressive pathology with unsa-
isfactory response to therapy and poor prognosis with a median
urvival of 7 months in the primary form and 2 months when it is
econdary.4 To date, most publications are based on case reports
nd series that rarely exceed 20 cases; therefore, the deﬁnition of
iological, clinical, and prognostic features of the disease remains
hallenging.1 Therapy is generally based on expert opinion, extrap-
lation from results obtained in patients with MM,  single case
eports or small retrospective studies.4 Therapeutic options vary
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widely and include vincristine, adriamycin and dexamethasone
(VAD) or melphalan based regimens. New therapeutic armamen-
taria with proteasome inhibitor bortezomib, immunomodulatory
drugs and stem cell transplantation were recently introduced.3
The authors report a case of a primary PCL treated with the VAD
regimen.
Case report
A 51-year old man  with no signiﬁcant past medical history pre-
sented with generalized bone pain, fatigue and >10% weight loss
in the previous month. Physical examination was unremarkable
with the exception of bone pain at palpation of lumbar column, ribs
and hips. Laboratory investigation (Table 1) revealed acute kidney
failure and macrocytic anaemia. Peripheral blood smear showed
leukocytosis with 39% (6.800/#mL) plasma cells.
The core biopsy presented hypercellular bone marrow with
plasma cell invasion (90% of the total population). The immunohis-
tochemistry study of cells exhibited CD56 and CD138 expression
and cytoplasmic lambda light chain restriction (Fig. 1).
Plasma cell karyotype was normal and FISH analysis revealed
12% positivity for del(13) and 48% positivity for t(11;14).
Serum protein electrophoresis demonstrated a discrete mono-
clonal spike at gamma  globulin level, identiﬁed as free lambda
chain on immunoﬁxation. An additional analytic study showed
hypercalcemia, hypoalbuminemia, elevated #b2-microglobulin,
hypogammaglobulinemia and Bence–Jones proteinuria (Table 1).
d by Elsevier Espan˜a, S.L.U. This is an open access article under the CC BY-NC-ND
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Fig. 1. Immunohistochemistry study of the cells after bone marrow biopsy revealed expr
light  chain restriction (B).
Table 1
Patient’s analytic results.
Parameter Reference
value
First analytic
evaluation
Urea (mg/dL) 17–50 137
Creatinine (mg/dL) 0.70–1.20 4.6
Total calcium, corrected (mg/dL) 8.4–10.2 11.7
Ionized calcium (mmol/L) 1.13–1.32 1.57
Albumin (g/dL) 3.5–5.2 3.1
LDH (U/L) 240–480 268
#b2-microglobulin (ng/mL) 800–2200 33 307
IgA  (mg/dL) 70–400 21
IgG  (mg/dL) 700–1600 385
IgM  (mg/dL) 40–230 16
Lambda light chain, serum (mg/dL) – 374.0
Kappa light chain, serum (mg/dL) – 110.0
Lambda light chain, urine (mg/dL) – 678.0
Kappa light chain, urine (mg/dL) – 0.8
Proteinuria (g/24 h) 0.05–0.25 21.63
Microalbuminuria (mg/24 h) <30 104
Hemoglobin (g/dL) 13.3–17.7 8.1
Leukocytes (103/#mL) 4.0–10.0 17.4
Neutrophils 2.8–7.5 7.1 (41.0%)
Lymphocytes 1.5–3.5 2.4 (14.0%)
Monocytes 0.4–1.3 0.7 (4.0%)
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Platelets (103/#mL) 150–400 123
 skull X-ray demonstrated the characteristic “punched out”
esions of MM.  Thorax, abdomen and pelvis CT scan revealed mul-
iple osteolytic lesions in vertebral column, ribs and hips.
Secretory PCL diagnosis in stage III of the International Staging
ystem was made. Support therapy with ﬂuids, bisphosphonates,
orticosteroids and diuretics was initiated, with normalization
f calcium and creatinine levels. Chemotherapy with VAD was
egun with the intention to later perform an allogeneic bone mar-
ow transplant. Despite initial favourable hematologic response
o chemotherapy, the patient died 2 months after diagnosis with
osocomial pneumonia.
iscussion
Primary PCL is a rare disease characterized by a very aggressive
ourse and an unfavourable prognosis.1,3
Although MM and PCL have an identical malignant plasma cell
f origin and share some clinical characteristics (such as age, gen-
er, incidence of extramedullary disease and type of paraprotein
ecreted by the neoplastic cells), primary PCL has distinct pre-
enting features, response to chemotherapy and prognosis.4 The
lassic adverse prognostic factors seen in advanced aggressive MM
re usually encountered at presentation in primary PCL.5 Therefore,
reater awareness and early recognition of the characteristic bloodession of CD56 (not shown) and CD138 (A), and demonstrated cytoplasmic lambda
smear can be determinant in correctly diagnosing and initiating
appropriate therapy.
Our patient presented several markers of poor prognosis
(hypoalbuminemia, elevated #b2-microglobulin, renal insufﬁ-
ciency and hypercalcemia), suggesting the aggressive nature of
the disease. Skeletal survey evidenced multiple osteolytic bone
lesions, which that can be present in primary PCL but is usu-
ally more common in secondary PCL.2,5 In general, primary PCL
patients have a higher incidence of extranodal presentation, hyper-
calcemia and renal dysfunction,2,5 all of which occurred in our
patient. Renal failure occurs in up to 50% of patients with MM
and several factors contribute to this, including myeloma cast
nephropathy, hypercalcemia, light chain deposition, amyloidosis,
hyperuricemia, recurrent infections and drug toxicity (nonsteroidal
anti-inﬂammatory agents and bisphosphonates).6 Since renal dys-
function can jeopardize the chance of a cancer patient to receive
optimal treatment, the identiﬁcation and correction of potential
acute renal failure reversible causes is essential.
The surface immunophenotype of plasma cells in PCL, either
primary or secondary, is typically similar to bone marrow plasma
cells in MM.  However, in a high proportion of PCL patients (up to
80%), plasma cells lack the aberrant CD56 expression, which has
led some authors to consider the absence of CD56 as a hallmark of
PCL that could distinguish it from MM.7 The expression of CD56,
present in our patient, may  indicate that the immunophenotype is
not a pathognomonic ﬁnding or may  suggest that, in some cases,
PCL results from MM  evolution.
FISH analysis revealed del(13) and t(11;14), both already
described in the context of MM.8 Del(13) is related with a worse
prognosis, while t(11;14) appears to confer better survival and
response to treatment in MM patients. Perhaps this translocation
can have a different role in PCL, stimulating proliferation, as in the
case of mantle cell lymphoma.
Due to the rarity of PCL, no prospective randomized trials inves-
tigating treatment have been done. The principle of therapy is
achievement of complete remission with induction chemotherapy
followed by stem cell transplant. Multiple chemotherapy regi-
mens have been tried with a variable degree of success. Regarding
old standards of care, VAD therapy appears to be superior to
melphalan.9 The effect of immunomodulatory drugs has been dis-
appointing with thalidomide and experience with lenalidomide
is small, not allowing for any conclusions yet. The novel agent
bortezomib has greatly enhanced the initial response rate, but
did not attain the major corresponding improvement in overall
survival.10 Our patient had an induced remission with VAD. Unfor-
tunately, he had a common complication, an infection that ceased
of precociously the opportunity to receive a stem cell transplant.
Susceptibility to bacterial infections is very common and sev-
eral factors contribute to this: hypogammaglobulinemia (as was
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ocumented in our case), circulating regulatory cells that suppress
ormal antibody synthesis, abnormalities in complement function
nd drugs with immunosuppressive effect (ex. dexamethasone use
n our patient).
The prognosis for primary and secondary PCL is dismal with
 median survival of about 2–8 months. The use of novel agents
oes not overcome the negative prognosis of PCL as compared
ith MM,  and more research is needed, not only in terms of avail-
ble therapies, but also for identifying speciﬁc molecular pathways
esponsible for the neoplastic transformation of PCL cells.
onclusion
In summary, we describe a case of primary PCL with a short
nfavourable outcome that illustrates the importance to increase
ur knowledge of this rare and highly deadly entity, to permit better
valuation and treatment of these patients.onﬂicts of interest
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